As of 2025-05-20, the EV/EBITDA ratio of Nymox Pharmaceutical Corp (NYMX) is -1.60. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. NYMX's latest enterprise value is 18.78 mil USD. NYMX's TTM EBITDA according to its financial statements is -11.71 mil USD. Dividing these 2 quantities gives us the above NYMX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | - | - |
| Forward P/E multiples | - | - |
| Fair Price | - | - |
| Upside | - | - |
| Date | EV/EBITDA |